Literature DB >> 27593488

Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge.

Christopher P Karch1, Jianping Li2, Caroline Kulangara3, Sara M Paulillo3, Senthil K Raman3, Sharareh Emadi4, Anmin Tan4, Zeinab H Helal5, Qing Fan6, Mazhar I Khan7, Peter Burkhard8.   

Abstract

Current influenza vaccines should be improved by the addition of universal influenza vaccine antigens in order to protect against multiple virus strains. We used our self-assembling protein nanoparticles (SAPNs) to display the two conserved influenza antigens M2e and Helix C in their native oligomerization states. To further improve the immunogenicity of the SAPNs, we designed and incorporated the TLR5 agonist flagellin into the SAPNs to generate self-adjuvanted SAPNs. We demonstrate that addition of flagellin does not affect the ability of SAPNs to self-assemble and that they are able to stimulate TLR5 in a dose-dependent manner. Chickens vaccinated with the self-adjuvanted SAPNs induce significantly higher levels of antibodies than those with unadjuvanted SAPNs and show higher cross-neutralizing activity compared to a commercial inactivated virus vaccine. Upon immunization with self-adjuvanted SAPNs, mice were completely protected against a lethal challenge. Thus, we have generated a self-adjuvanted SAPN with a great potential as a universal influenza vaccine.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Flagellin; Influenza; M2e; Nanoparticle; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 27593488     DOI: 10.1016/j.nano.2016.08.030

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  19 in total

Review 1.  Advances in immunotherapy delivery from implantable and injectable biomaterials.

Authors:  David G Leach; Simon Young; Jeffrey D Hartgerink
Journal:  Acta Biomater       Date:  2019-02-13       Impact factor: 8.947

Review 2.  Tolerogenic Nanoparticles to Treat Islet Autoimmunity.

Authors:  Tobias Neef; Stephen D Miller
Journal:  Curr Diab Rep       Date:  2017-08-08       Impact factor: 4.810

Review 3.  Improving Vaccine and Immunotherapy Design Using Biomaterials.

Authors:  Michelle L Bookstaver; Shannon J Tsai; Jonathan S Bromberg; Christopher M Jewell
Journal:  Trends Immunol       Date:  2017-12-14       Impact factor: 16.687

Review 4.  Universal influenza vaccines: from viruses to nanoparticles.

Authors:  Ye Wang; Lei Deng; Sang-Moo Kang; Bao-Zhong Wang
Journal:  Expert Rev Vaccines       Date:  2018-11-02       Impact factor: 5.217

5.  Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.

Authors:  Zachary R Sia; Matthew S Miller; Jonathan F Lovell
Journal:  Mol Pharm       Date:  2020-08-17       Impact factor: 4.939

Review 6.  Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.

Authors:  Lampouguin Yenkoidiok-Douti; Christopher M Jewell
Journal:  ACS Biomater Sci Eng       Date:  2020-01-12

7.  Protein nanovaccine confers robust immunity against Toxoplasma.

Authors:  Kamal El Bissati; Ying Zhou; Sara Maria Paulillo; Senthil Kumar Raman; Christopher P Karch; Craig W Roberts; David E Lanar; Steve Reed; Chris Fox; Darrick Carter; Jeff Alexander; Alessandro Sette; John Sidney; Hernan Lorenzi; Ian J Begeman; Peter Burkhard; Rima McLeod
Journal:  NPJ Vaccines       Date:  2017-09-05       Impact factor: 7.344

Review 8.  Coiled-Coils: the Molecular Zippers that Self-Assemble Protein Nanostructures.

Authors:  Won Min Park
Journal:  Int J Mol Sci       Date:  2020-05-19       Impact factor: 5.923

Review 9.  Controlling timing and location in vaccines.

Authors:  Darrell J Irvine; Aereas Aung; Murillo Silva
Journal:  Adv Drug Deliv Rev       Date:  2020-06-26       Impact factor: 15.470

10.  Comparison of the efficacy of a commercial inactivated influenza A/H1N1/pdm09 virus (pH1N1) vaccine and two experimental M2e-based vaccines against pH1N1 challenge in the growing pig model.

Authors:  Tanja Opriessnig; Phillip C Gauger; Priscilla F Gerber; Alessandra M M G Castro; Huigang Shen; Lita Murphy; Paul Digard; Patrick G Halbur; Ming Xia; Xi Jiang; Ming Tan
Journal:  PLoS One       Date:  2018-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.